Report Library
All ReportsDatamonitor Healthcare I&I Disease Analysis: Wet Age-Related Macular Degeneration (Wet AMD)
December 28, 2023
Due to their ability to improve clinical outcomes and treat a more comprehensive patient population, vascular endothelial growth factor (VEGF) inhibitors have become the standard treatment used in wet AMD.
Even with Roche’s efforts to position Lucentis ahead of Avastin, and the introduction of Eylea into the market, bevacizumab’s low price continues to lead to off-label use in wet AMD. Although the treatment of cancer with bevacizumab can be costly, a much smaller dose of 1.25mg is used in wet AMD, dropping the cost of the drug to approximately $50 per dose. By comparison, a single dose of Lucentis costs approximately $1,950.
This Datamonitor Healthcare report contains a Disease Analysis module.
Indications Covered: | Wet Age-Related Macular Degeneration (Wet AMD) (Ophthalmology) |